Entecavir and TLR7 Agonist Combination for HBV Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus infection lack potent therapeutic agents, necessitating the development of more effective combinations to combat the virus effectively.
Innovation Solution
A pharmaceutical combination of a TLR7 agonist, represented by a compound of formula I, and entecavir is administered in various dosages and frequencies to enhance the immune response against HBV, either as a fixed or non-fixed combination, with potential administration routes including oral and parenteral methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs (nucleosides/nucleotides) are used to inhibit HBV DNA replication, then viral replication is suppressed, but treatment efficacy is insufficient and potent therapeutic agents are lacking
Solution Approach 1:
The patent combines entecavir (a nucleoside analog that inhibits HBV DNA replication) with a TLR7 agonist (which stimulates immune response) into a fixed pharmaceutical combination. This merging of two different mechanisms of action addresses the insufficiency of conventional monotherapies by simultaneously suppressing viral replication and enhancing immune clearance, thereby improving overall treatment efficacy.
2Reliability
If TLR7 agonist alone is used to stimulate immune response, then immune activation occurs, but viral replication inhibition is insufficient
Solution Approach 1:
The fixed combination integrates the TLR7 agonist (for immune activation) with entecavir (for viral replication inhibition) in specific dosage ratios. This combination ensures that while the TLR7 agonist stimulates robust immune response, the entecavir component simultaneously suppresses viral replication, compensating for the TLR7 agonist's insufficient antiviral effect when used alone.
3Reliability
If combination therapy is developed to improve treatment efficacy, then therapeutic potency increases, but drug combination complexity increases
Solution Approach 1:
The patent creates a fixed combination formulation where entecavir and TLR7 agonist are pre-combined in specific dosage ratios (e.g., 1:10 to 10:1 weight ratios). This fixed combination simplifies clinical administration compared to separate dosing regimens, while maintaining the synergistic therapeutic effect. The formulation complexity is managed through predefined dosage forms such as tablets or capsules containing both active ingredients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly reduces HBV DNA levels and enhances treatment efficacy compared to monotherapies, demonstrating a synergistic effect in reducing viral markers.
Implementation Method 1
Toll-like receptors are stimulated by corresponding PAMPs or DAMPs to induce signaling cascade, leading to activation of transcription factors such as AP-1, NF-κB and interferon regulatory factors (impulse response function). As such, a variety of cellular reactions are induced, including production of interferons, proinflammatory cytokines and effector cytokines, thus promoting immune response.
Implementation Method 2
Toll-like receptor 7 (TLR7) is mainly expressed by plasmacytoid dendritic cells (pDCs) and induces secretion of the interferon alpha (IFN-α) by ligand recognition.
Implementation Method 3
Nucleosides (nucleotides), such as entecavir, can inhibit HBV DNA replication.
Data Source
Figure 1
AI summary
A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.